Nurix Therapeutics (NASDAQ:NRIX) Given New $40.00 Price Target at Stifel Nicolaus

11 Jul 2026, 10:40 by Scott Moore · The Cerbat Gem

Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price target raised by Stifel Nicolaus from $34.00 to $40.00 in a research note released on Friday, MarketBeat reports. They currently have a buy rating on the stock.

Several other analysts have also recently weighed in on NRIX. Jefferies Financial Group lifted their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Oppenheimer started coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They issued an “outperform” rating and a $28.00 price objective for the company. Royal Bank Of Canada lifted their target price on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday. Truist Financial boosted their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Finally, HC Wainwright increased their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.77.

Check Out Our Latest Stock Report on Nurix Therapeutics

Nurix Therapeutics Trading Down 6.6%

NASDAQ NRIX traded down $1.63 on Friday, hitting $23.06. The company’s stock had a trading volume of 1,552,950 shares, compared to its average volume of 2,287,902. Nurix Therapeutics has a 52-week low of $8.19 and a 52-week high of $25.08. The company’s 50-day simple moving average is $18.44 and its 200 day simple moving average is $17.37. The firm has a market cap of $2.38 billion, a P/E ratio of -7.30 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.09). The business had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 73.57%. On average, research analysts forecast that Nurix Therapeutics will post -2.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 5,394 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the sale, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. This represents a 4.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 25,051 shares of company stock worth $434,466. Company insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NRIX. Larson Financial Group LLC grew its holdings in shares of Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Nurix Therapeutics by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after purchasing an additional 1,476 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at $31,000. Royal Bank of Canada increased its holdings in Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after buying an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Nurix Therapeutics by 8.2% in the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after buying an additional 1,674 shares during the last quarter.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.